COVID-19 vaccine(Dollvet Veterinary Vaccine Pharmaceutical Biological Substance Production Industry Co., Ltd.)(COVID-19 vaccine(Dollvet Veterinary Vaccine Pharmaceutical Biological Substance Production Industry Co., Ltd.)) - 药物靶点：SARS-CoV-2 antigen_在研适应症：新型冠状病毒感染_专利_临床

概要

基本信息

药物类型

预防性疫苗

别名

TURKOVAC-Dollvet

靶点

SARS-CoV-2 antigen

作用方式

抑制剂

作用机制

新冠病毒抗原抑制剂

治疗领域

感染呼吸系统疾病

在研适应症

新型冠状病毒感染

非在研适应症-

原研机构

Dollvet Veterinary Vaccine Pharmaceutical Biological Substance Production Industry Co., Ltd.

在研机构

Health Institutes of Turkey

非在研机构-

权益机构-

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

6

项与 COVID-19 vaccine(Dollvet Veterinary Vaccine Pharmaceutical Biological Substance Production Industry Co., Ltd.) 相关的临床试验

NCT05230940

/ Completed临床2期IIT

Multicenter,Randomized,Observational Blind Phase IIB Clinical Trial to Evaluate the Effectiveness,Immunogenicity and Safety of Two Doses of CoronaVac (Sinovac) Vaccine Against Two Doses of Inactivated COVID-19 Vaccine (TURKOVAC) in Healthy Adolescent (12-18 Years) Subjects

This study is a multi-center, randomized, national, observer-blinded, active-controlled phase IIB clinical trial to determine the efficacy, immunogenicity, and safety of two-doses of inactive COVID-19 vaccine (TURKOVAC) vaccine versus the two-doses CoronaVac (Sinovac) vaccine in healthy adolescents aged 12-18 years.

开始日期2022-02-18

申办/合作机构

Health Institutes of Turkey

NCT05210179

/ Completed临床2期IIT

Open-Label, Two Arms, Multi-Centered, Phase 2b Clinical Trial to Determine the Safety, Efficacy, and Immunogenicity of Booster Vaccination (TURKOVAC) Against SARS-CoV-2

This study is open-label, two arms, multi-centered, phase 2b clinical trial to determine the efficacy, safety, and immunogenicity of booster vaccination (TURKOVAC) against Covid-19.
The primary aim of the study is to evaluate the efficacy of a booster dose of TURKOVAC vaccine administered to subjects who have passed at least 90 days and at most 240 days after the second dose of the first course of Comirnaty (Code name: BNT162b2) vaccine.

开始日期2022-01-24

申办/合作机构

Health Institutes of Turkey

NCT05077176

/ Completed临床3期IIT

Open Label, Multi-Center Phase 3 Clinical Trial to Determine Safety, Efficacy, and Immunogenicity of Booster Vaccination Against SARS-CoV-2

The inactivated Booster Phase 3 study aims to determine the efficacy, safety, and immunogenicity of inactivated COVID-19 vaccines in subjects with a minimum of 90 days and a maximum of 270 days after the second dose of CoronaVac vaccine.

开始日期2021-10-08

申办/合作机构

Health Institutes of Turkey

100 项与 COVID-19 vaccine(Dollvet Veterinary Vaccine Pharmaceutical Biological Substance Production Industry Co., Ltd.) 相关的临床结果

登录后查看更多信息

100 项与 COVID-19 vaccine(Dollvet Veterinary Vaccine Pharmaceutical Biological Substance Production Industry Co., Ltd.) 相关的转化医学

登录后查看更多信息

100 项与 COVID-19 vaccine(Dollvet Veterinary Vaccine Pharmaceutical Biological Substance Production Industry Co., Ltd.) 相关的专利（医药）

登录后查看更多信息

12

项与 COVID-19 vaccine(Dollvet Veterinary Vaccine Pharmaceutical Biological Substance Production Industry Co., Ltd.) 相关的文献（医药）

2025-02-01·American Journal of Public Health

Erratum In: “Health Care Delivery Site– and Patient-Level Factors Associated With COVID-19 Primary Vaccine Series Completion in a National Network of Community Health Centers”

2024-12-31·Human Vaccines & Immunotherapeutics

The impact of previous SARS-CoV-2 infection on post-vaccine adverse events in individuals vaccinated with TURKOVAC or CoronaVac –inactivated COVID-19 vaccines

Article

作者: Aydos, Omer ; Arslan, Sonay ; Altuntas Aydin, Ozlem ; Ayhan, Muge ; Ozalp, Onur ; Yildiz, Orhan ; Unuvar, Gamze Kalin ; Gunduz, Alper ; Kaya Kalem, Ayse ; Onal, Ugur ; Hasanoglu, Imran ; Celik, Ilhami ; Cagkan Inkaya, Ahmet ; Akhan, Sila ; Gorkem Er, Ahmet ; Unal, Serhat ; Kayaaslan, Bircan ; Kara, Ates ; Guner, Rahmet ; Sabirli, Soner ; Bayraktar, Zeynep ; Durusu Tanriover, Mine ; Yuce, Zeynep Ture ; Gamze, Gamze ; Demir, Omer ; Toker, Aysin Kilinc ; Ates, Ihsan ; Ozdarendeli, Aykut ; Kose, Sukran ; Akalin, Emin Halis ; Coskun, Belgin

This study- a secondary analysis of data from a randomized, observer-blinded, non-inferiority study among volunteers between 18-55 y old in Türkiye- evaluated the impact of previous SARS-CoV-2 infection before the first dose of inactive TURKOVAC on post-vaccine local and systemic adverse events (AEs) comparing with CoronaVac. Of 1266 participants analyzed, 27.7% had a previous COVID-19 history. Local and systemic AEs were observed in 37.3% and 39% of the participants. The frequency of AEs was slightly higher in the first 30 minutes and 24 hours among participants with a COVID-19 history; none were severe. 1203 participants had a second dose vaccination, and 27.3% had a history of COVID-19. The frequencies of local and systemic AEs after the second dose were similar between those with and without a COVID-19 history. The TURKOVAC and CoronaVac showed similar frequencies of local and systemic AEs in the first 30 minutes after vaccination.

2024-01-01·Therapeutic Advances in Vaccines and Immunotherapy

Relative effectiveness of COVID-19 vaccine booster doses in people aged 65 and older—a retrospective cohort study in Türkiye

Article

作者: Sarisaltik, Alican ; Sezerol, Mehmet Akif

Background: Immunization in the elderly population is critical due to the high frequency of health outcomes related to COVID-19. Objectives: This study aimed to compare the effectiveness levels of COVID-19 vaccine schedules in preventing SARS-CoV-2 infection in the older adult group who received at least one booster dose. Design: Retrospective cohort study. Methods: This study evaluated 8969 adults aged 65 and over in the Sultanbeyli district of İstanbul. COVID-19 vaccination and SARS-CoV-2 polymerase chain reaction testing data between January 14, 2021 and December 2, 2022 were obtained from the National Public Health Management System. Results: The median age of participants was 71 years. The vaccines were mostly administered as CoronaVac for the first and second doses (81.4% and 82.2%, respectively) and BNT162b2 for the third and fourth doses (61.8% and 73.1%, respectively). Turkovac was administered only in booster doses (third dose 0.6%, fourth dose 4.8%). The adjusted relative vaccine effectiveness (rVE) was found to be 61.8% (95% confidence interval (CI) 51.5–69.9) in two doses of inactivated vaccine and one dose of mRNA vaccine schedule compared to the homolog booster of CoronaVac primary vaccine schedule. In two booster doses receipts, the adjusted rVE was found to be 45.4% (95% CI 13.8–65.4) in three doses of inactivated and one dose mRNA vaccine schedule and 43.0% (95% CI 20.5–59.2) in two doses of inactivated and two doses of mRNA vaccines schedule compared to the two homolog boosters with CoronaVac primary vaccine schedule. Conclusion: In this study, the effectiveness of the mRNA vaccine as a booster dose was higher than that of the homologous boosters in participants receiving the CoronaVac primary series for those aged 65 and over.

100 项与 COVID-19 vaccine(Dollvet Veterinary Vaccine Pharmaceutical Biological Substance Production Industry Co., Ltd.) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
新型冠状病毒感染	临床3期	土耳其	Health Institutes of Turkey	2021-06-21

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04942405 (Pubmed) 人工标引	临床3期	-	1,290	TURKOVAC	(鬱襯積糧選鹹簾鏇襯膚) = 簾簾選壓鏇網蓋窪顧獵鹽艱醖糧簾築蓋鏇鏇膚 (鏇獵醖遞築蓋簾醖觸顧, 12.95 ~ 60.06) 更多	优效	2022-11-04
				SARS-CoV-2 Inactivated Vaccine	(獵蓋窪鬱艱鏇範蓋窪鏇) = 衊鹹窪製餘鏇構構鑰齋選築繭鹹憲壓壓醖積淵 (網簾鹽構製構構顧襯醖 )